How We Evaluate Health Research: Biohacking India Evidence Standards

“Magnesium works.” “Seed oils are inflammatory.” “High HDL is good.” “This test detects mitochondrial dysfunction.” None of these statements is precise enough to evaluate properly.

Before I decide what I think, I want the question to be clear. Who are we talking about? Compared with what? At what dose or exposure? For how long? Which outcome are we measuring: symptoms, a biomarker, disease risk, diagnosis, treatment response or a long-term clinical outcome?^[1]

The comparator is especially important in nutrition. Replacing one food with another is not the same question as adding that food on top of the existing diet. The same intervention can look useful, neutral or harmful depending on what it replaces.

A study can be beautifully conducted and still be irrelevant if it studied the wrong population, formulation, dose, comparator or endpoint. I would rather have one study that directly answers the question than ten papers that are only vaguely related to it.

Ten weak papers do not automatically beat two strong ones.

If the question is whether an intervention improves a human outcome, randomized human evidence usually carries much more weight than an animal experiment or a cell pathway. For diagnosis, prognosis, harms or long-term exposures, different designs may be more useful. There is no single evidence ladder that answers every question mechanically.^[2]

What matters is what a study design can actually establish.

For intervention effects, well-conducted randomized human trials usually carry the most weight, especially when results replicate. Observational studies can be valuable but remain vulnerable to confounding and reverse causality. Case reports and personal experience can reveal signals. Animal and cell studies can explain mechanisms and generate hypotheses.^[2]

They are not interchangeable forms of proof.

This is why I do not use “research-backed” to mean “I found a paper.” Quality, relevance and direction of evidence matter far more than citation count.

For interventions I teach in the Biohacking Mastery Course, my minimum evidence floor is that the intervention is backed by at least one relevant randomized controlled trial where that claim is being made. I think this is a useful floor because an intervention should have more behind it than a theory, an anecdote or a mechanistic argument.

But one RCT does not end the analysis.

I still want to know whether randomization and comparison were credible, the trial was large enough, the outcome mattered, the effect was meaningful and precise, dropouts were handled well, subgroup results were credible, and the tested dose and form match the claim.^[3]

Then I look outside it. Has the result replicated? What did other trials find? Is there a systematic review? Does the effect survive stronger methods? Does the population match the people I want to apply it to? What does the safety evidence show?^[2]

A single positive RCT can justify taking an intervention seriously. It does not automatically justify certainty.

Statistical significance is not the finish line either. A tiny effect can be statistically significant in a very large study and still matter very little in practice. I care about effect size, uncertainty and whether the outcome matters to the person making the decision.

Mechanisms are one of the easiest places to become overconfident in health science.

If a compound changes a pathway in a cell, and that pathway is linked to a disease, it is tempting to conclude that the compound will improve the disease. It might. The mechanism makes the idea plausible. It does not prove the clinical effect.

Animal data can also teach us a lot about biology and generate hypotheses, but an animal experiment cannot substitute for human outcome evidence when the claim is about humans.

Sometimes a study measures a stand-in for the outcome we actually care about. Researchers call this a surrogate outcome or surrogate endpoint. A treatment may improve a laboratory marker without improving how people feel, function or survive. Some surrogates are well validated. Others are simply convenient measurements.^[5]

I use mechanisms to understand why a result might make sense, explain discordant findings and generate better questions. I do not use an elegant mechanism to overrule stronger human evidence pointing the other way.

When two good studies appear to disagree, my first reaction is not to choose the one I prefer.

I ask what changed: population, starting status, dose, formulation, duration, adherence, comparator, other interventions, outcome, assay, follow-up or methodology. For example, two vitamin D trials can point in different directions if one mostly enrolled people who were deficient and the other people who were already replete. The intervention may look similar while the starting biology is not.

Very often the contradiction becomes smaller once the question is defined properly.

Replication matters. One exciting result deserves attention; a result that appears again across independent studies, stronger methods and different populations deserves more confidence. If stronger studies repeatedly fail to reproduce it, confidence should fall.^[2]

I actively want to see the strongest evidence against my current view. If an argument only works when contrary studies are left out, it is not a strong argument.

A biomarker can predict disease without causing it. People who take a supplement may also exercise more, eat differently or use healthcare differently from people who do not. If supplement users have better outcomes, the supplement is only one possible explanation. A disease can also change a biomarker, making the direction of cause and effect look backwards.

Before I use associative evidence causally, I ask what else could explain it: reverse causality, baseline health, smoking, activity, diet, socioeconomic differences, treatment indication, medication use, healthcare access or other confounders.

Then I look for evidence that separates those explanations. Randomized, prospective or genetic evidence may help depending on the question. Mechanistic evidence can add coherence. Several independent lines of evidence pointing the same way are more persuasive than repeating the same confounded association.

This matters directly to root-cause analysis.

When I use that phrase, I do not mean that every complex chronic condition has one hidden cause that can always be discovered. I mean that instead of stopping at the symptom or abnormal marker, I investigate plausible upstream and contributing drivers, rank them by evidence and relevance, rule factors in or out as far as is useful, and focus on the ones that can actually change the plan.

There is a point where more testing stops adding value. I am not interested in chasing perfect certainty if the next test is unlikely to change what we do.

A laboratory flag answers a narrow question. It tells you whether a result fell outside that laboratory's reported reference interval. A clinical decision threshold is a different thing.^[6][7]

A reference interval usually describes results in a selected reference population. A clinical decision threshold is tied to a specific diagnosis, risk or treatment decision. One does not automatically tell you the other.^[6][7]

When I build or evaluate biomarker ranges, I prefer thresholds tied to meaningful outcomes, validated diagnostic cut-offs or intervention-response data where those exist. Age, sex, assay method, specimen type and clinical context can change interpretation. If the evidence does not justify calling a range “optimal,” I do not think ideology should fill the gap.

The measurement itself also has to be trustworthy. Fasting status, time of day, exercise, posture, sample storage, medications, supplements, acute illness and laboratory method can all affect a result. When a value makes no biological sense, the first question is sometimes not “what disease causes this?” but “can I trust the measurement?”

Commercial availability is not validation either. Before I take a test seriously, I want to know whether it measures what it claims reliably, whether the result maps to something clinically meaningful and whether knowing the answer will change a decision.^[5]

“Vitamin D works” or “curcumin works” is still too vague even when good trials exist.

A trial of a specific vitamin D dose in people who are deficient does not automatically answer what that dose does in someone already replete. Form, dose, route, duration, baseline status and outcome all matter.

That is why I pay close attention to the forms, combinations and doses used in human trials. They are an evidence anchor. I then judge whether the study applies to the person in front of me and whether the plan is practical enough to follow.

Safety is part of efficacy, not an appendix. I look for contraindications, known interactions, adverse-event data and reasons a result from the average trial participant may not apply to a particular person. Pregnancy, significant disease, medications and other high-risk contexts can change the decision substantially.

Biohacking India's consultation work focuses on nutrition, lifestyle, supplements, biomarker interpretation and diagnostics-driven reasoning within our scope. It does not replace physician-led diagnosis of certain conditions or emergency care. Where prescriptions, medical or specialist management are required, we work alongside or refer to appropriately qualified clinicians.

There is a real difference between possible, suggests, likely and shown to.

I do not want to upgrade “promising” into “proven” because stronger language sounds better. I also do not want to hide a clear conclusion behind vague hedging when the evidence is genuinely strong.

The amount of evidence needed to act depends on the stakes. A low-cost, low-risk lifestyle change does not require the same certainty as an invasive treatment or a decision that could delay appropriate medical care. When the downside of being wrong is large, the evidence threshold should rise.

Sometimes the correct conclusion is simply that I do not know yet. That is more useful than manufacturing an answer from weak evidence.

My own health history is one reason I became obsessive about diagnostics and research. It generated questions I probably would not have asked otherwise. Client experiences can do the same.

But improvement after an intervention does not by itself prove why it improved. Symptoms fluctuate. Several things may have changed together. Regression to the mean is real. Expectations and adherence change. The underlying condition may change independently.

I use personal observations to generate hypotheses, decide what to investigate and see what is worth monitoring. I do not treat them as equivalent to controlled evidence.

Testimonials should be read the same way: they tell you what one person experienced. They are not a substitute for evidence about expected effects in a population.

Funding or a commercial interest does not make a study automatically wrong. It does give me another reason to inspect the methods, outcome selection, reporting and interpretation carefully.^[8]

The same standard should apply to us. If Biohacking India has a material commercial or referral relationship relevant to a recommendation, that relationship should be disclosed in the relevant context. Selling something is not evidence that it works. Neither is disliking an industry evidence that its product does not work.

The claim still has to stand on the evidence.

AI is useful for reducing mechanical work: finding candidate papers, organizing research, extracting structured details, comparing studies, generating better search terms and surfacing contradictions that deserve a closer look.

The failure mode is obvious. An AI answer can be wrong. A citation can exist but fail to support the sentence attached to it. A model can mix populations, doses or outcomes and produce a confident synthesis that the underlying papers do not justify.

For consequential scientific claims, the source has to be checked. I want to know what the paper actually studied and whether it supports the exact proposition being made. If the citation does not entail the claim, the fact that an AI produced it quickly is irrelevant.

AI is a research assistant. It is not a scientific authority, and its output is not a layer of evidence above the underlying sources.

I have changed my views on health topics before, sometimes after being very confident about them. I expect that to happen again.

When better evidence changes the conclusion, I would rather state the change than defend an older position because I am attached to it. If I find an error in a public scientific claim, the correct response is to correct the claim and make the important change visible. There is no value in inventing an arbitrary update schedule; the useful trigger is a material change in evidence, an identified error or a real review event.

The standard I want people to be able to hold me to is straightforward. Ask what exact claim I am making. Ask what the strongest evidence for it is. Ask what the best evidence against it is. Ask what would change my mind. If I cannot answer those questions, the claim is not ready to be stated with strong certainty.